Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3595-3603

  Small, Eric J ^a   Frohlich, Mark W ^a   Bok, Robert ^a   Shinohara, Katsuto ^a   Grossfeld, Gary ^a   Rozenblat, Zinovi ^a   Kelly, Wm Kevin ^a   Corry, Michele ^a   Reese, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; KETOCONAZOLE; PC SPES; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFECT; GYNECOMASTIA; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM;

EID: 0034330147     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3595     Document Type: Article

References (41)

1. Survey of UsToo members and other prostate cancer patients to evaluate the efficacy and safety of PC-SPES
2. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
3. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease
4. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer
5. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients
6. Effects of baicalein and esculetin on transduction signals and growth factor expression in T-lymphoid leukemia cells
7. Effect of glycyrrhetinic acid on DNA damage and unscheduled DNA synthesis induced by benzo(alpha)pyrene
8. Inhibition of mutagenicity in Salmonella typhimurium by Glycyrrhiza glabra extract, glycyrrhizic acid, 18 alpha and 18 beta-glycyrrhetinic acids
9. Identification of antimicrobial and antioxidant constituents from licorice of Russian and Xinjiang origin
10. Reversal of daunomycin and vinblastine resistance in multi-drug resistant P388 leumemia in vitro through enhanced cytotoxicity by triterpenoids
11. Preventive effect of ginseng intake against various human cancers: A case-control of 1987 pairs
12. Anticarcinogenic effect of long-term oral administration of red ginseng on newborn mice exposed to various chemical carcinogens
13. In vitro induction of differentiation by ginsenoides in F9 teratocarcinoma cells
14. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside Rb2, 20 (R)- and 20 (S)-ginsenoside-Rg3, of red ginseng
15. Inhibition of tumor angiogenesis and metastasis by saponin of Panax ginseng, ginsenoside-Rb2
16. Antitumor active polysaccharides from the Chinese mushroom songshan lingzhi, the fruiting body of Ganoderma tsugae
17. Antitumor active protein-containing glycans from the Chinese mushroom songshan lingzhi, Ganoderma tsugae mycelium
18. Antitumor activity of Sarcondon aspratus (Ber.) S. Ita and Ganoderma lucidum (Fr.) Karst
19. Effects of Ganoderma lucidum and krestin on cellular immunocompetence in gamma-ray-irradiated mice
20. Complete amino acid sequence of an immunomodulatory protein, ling Zhi-8: An immunomodulator from a fungus, Ganoderma lucidum, having similarity to immunoglobulin variable regions
21. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives
22. Cell death induced by baicalein in human hepatocellular carcinoma cell lines
23. Antitumor effects of saikosaponins, baicalin, and baicalein on human hepatoma cell lines
24. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES
25. PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo
26. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer
27. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
28. A modification of Simon's optimal design for phase II trials when the criterion is median sample size
29. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
30. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study
31. Steroid hormone binding proteins in a blood plasma
32. Acid phosphatase: Defining a role in androgen-independent prostate cancer
33. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
34. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer
35. Unconventional medicine in the United States: Prevalence, costs, and patterns of use
36. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiological analysis
37. Alternative medicine: The risks of untested and unregulated remedies
38. A phase 1- 2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma
39. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxy-progesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762
40. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol
41. Idiopathic thromboembolism as the presenting sign of occult prostate cancer